What new drugs should you know about from the second quarter of 2018? Scroll through our quick slideshow to find out.
Meta-Analysis Finds High Uptake but Moderate Adherence in Clinical Trials of Depression and Anxiety Apps
Mental health apps show high initial uptake but moderate adherence, revealing key factors for improving user retention in clinical trials.
Weekly Dose Podcast: FDA Breakthrough in Acromegaly, Alcohol–Dementia Risk Clarified, Tirzepatide in Youth T2D, Precision Mood Gains, and Major Contraception Practice Insights
Topics include new findings on oral acromegaly therapy, alcohol and dementia risk, tirzepatide in youth T2D, precision mood care, and LARC outcomes.
Otsuka Submits NDA to FDA for Centanafadine for Treatment of ADHD Across the Lifespan
Otsuka seeks FDA approval for centanafadine, a novel ADHD treatment showing significant efficacy and safety in pivotal trials for all age groups.
Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes
Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.
Atopic Dermatitis Signs and Symptoms for Referral: Physical and Emotional Expertise
Primary care is the ideal setting for management of atopic dermatitis, but certain scenarios, both physical and psychological, call for expert referral.
J&J's Investigational Anti-Tau Alzheimer Drug Posdinemab Fails to Meet Primary Endpoint in Phase 2b Trial
J&J halts phase 2b AuTonomy trial after anti-tau antibody posdinemab fails to slow clinical decline, marking another setback for tau-targeting therapeutics.